Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | HPGD | P15428 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16560516 | 0.90 | POLB (1.00) | POLBSMN1; SMN2HPGDALDH1A1HTT | |
| SCHEMBL16557563 | 0.88 | HPGD (0.83) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL16557481 | 0.88 | MEN1 (0.76) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15583940 | 0.83 | HPGD (1.00) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL16557567 | 0.82 | HPGD (0.82) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15583802 | 0.81 | HPGD (0.84) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15583867 | 0.80 | HPGD (0.79) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15583885 | 0.79 | HPGD (1.00) | POLBSMN1; SMN2HPGDMEN1KMT2A | |
| SCHEMBL15583871 | 0.79 | HPGD (1.00) | POLBSMN1; SMN2HPGDTP53ALDH1A1 | |
| SCHEMBL15583808 | 0.78 | HPGD (0.79) | POLBSMN1; SMN2HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | POLB 1826/4885SMN1; SMN2 3855/4885HPGD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.